

Welcome to STN International! Enter x:x

LOGINID:sssptal621vxo

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'CAPLUS' AT 16:10:16 ON 06 JUL 2007
FILE 'CAPLUS' ENTERED AT 16:10:16 ON 06 JUL 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	54.87	227.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.02	-7.02

=>


Uploading C:\Program Files\Stnexp\Queries\910.str

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:10:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 58545 TO ITERATE

100.0% PROCESSED 58545 ITERATIONS
SEARCH TIME: 00.00.01

35 ANSWERS

L8 35 SEA SSS FUL L7

L9 2 L8

=> d 1-2 ibib abs hitstr

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:964817 CAPLUS
DOCUMENT NUMBER: 141:410756
TITLE: Preparation of macrocyclic compounds for the treatment of inflammation and autoimmune disorders
INVENTOR(S): Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange, Jean-Christophe; Inoue, Atsushi; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Matsushima, Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai, Hideki; Shen, Yong-chun; Shirota, Hiroshi; Spyvee, Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto, Satoshi; Yoneda, Naoki
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl. No. PCT/US03/07377.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004224936	A1	20041111	US 2003-657910	20030909
WO 2003076424	A1	20030918	WO 2003-US7377	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005023792	A2	20050317	WO 2004-US29196	20040909
WO 2005023792	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.:

US 2002-362883P P 20020308

US 2002-380711P P 20020514
WO 2003-US307377 A2 20030307
US 2003-657910 A 20030909

OTHER SOURCE(S):
GT

MARPAT 141:410756



AB Macroyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH₂; n = 0-2; X = absent, O, NH, N-alkyl, CH₂, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NF- κ B with IC₅₀ values < 10 μ M.

IT	603039-45-8P	603045-38-1P	603045-40-5P
	603045-42-7P	603045-44-9P	603045-46-1P
	603151-24-2P	603151-32-2P	603151-34-4P
	603959-45-1P	603985-37-1P	603985-63-3P
	603985-65-5P	603985-69-9P	603985-71-3P
	603985-72-4P	603985-73-5P	603985-74-6P
	603985-75-7P	603985-77-9P	603985-78-0P
	603986-04-5P	603987-34-4P	603987-35-5P
	603987-75-3P	603987-93-5P	603988-36-9P
	791101-13-8P	791101-14-9P	791101-15-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (9CI)
(CA INDEX NAME) .

Absolute stereochemistry.
Double bond geometry as shown




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4S,5Z,8S,9S,11E)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603959-45-1 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-37-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-65-5 CAPLUS
CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-69-9 CAPLUS
CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-71-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-72-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-73-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-74-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-75-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-,

(3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


=O

RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

=O

RN 603985-78-0 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603986-04-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603987-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603987-75-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-
8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603987-93-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-
8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8S,9S,11E)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-,

(3S,4R,5Z,8S,9R,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9R,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 791101-14-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(methylamino)ethoxy]-, (3S,4R,5Z,8S,9R,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 791101-15-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737744 CAPLUS

DOCUMENT NUMBER: 139:261090

TITLE: Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses

INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.; Diepitro, Lucian; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Gilbert, Sandra; Goto, Masaki; Harmange, Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan; Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi Eisai Co. Ltd., Japan; et al.

PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 438 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076424	A1	20030918	WO 2003-US7377	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478065	A1	20030918	CA 2003-2478065	20030307
AU 2003224672	A1	20030922	AU 2003-224672	20030307
BR 2003008113	A	20050209	BR 2003-8113	20030307

EP 1507773	A1	20050223	EP 2003-721353	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200519954	T	20050707	JP 2003-574642	20030307
CN 1653059	A	20050810	CN 2003-810248	20030307
US 2004224936	A1	20041111	US 2003-657910	20030909
IN 2004KN01270	A	20060714	IN 2004-KN1270	20040830
NO 2004004256	A	20041207	NO 2004-4256	20041007
US 2006247448	A1	20061102	US 2004-507067	20041110
ITY APPLN. INFO.:			US 2002-362883P	P 20020308
			US 2002-380711P	P 20020514
			WO 2003-US7377	W 20030307

OTHER SOURCE(S): MARPAT 139:261090
GI



AB . Macroyclic lactones and lactams, such as I [R1 = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R2, R3 = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2 or R1R3 = 3-8 membered alicyclic ring; R4 = H, halogen; R5 = H, hydroxyl protecting group, linked prodrug; R6, R7 = H, OH, protected hydroxyl; R8, R9, R10, R11 = H, OH, NH₂, alkoxy, alkylamino, etc.; X = O, NH, S, CH₂, etc.; R8R9 = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF- κ B, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The

prepared macrocycles were assayed for their effect on TNF- α and β -actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells.

IT 603044-46-8P 603045-38-1P 603045-40-5P
603045-42-7P 603045-44-9P, ER 807563
603045-45-0P 603045-46-1P 603151-24-2P, ER
803064 603151-32-2P 603151-34-4P, ER 804019
603985-37-1P 603985-63-3P 603985-64-4P
603985-65-5P 603985-69-9P 603985-70-2P, ER
804606 603985-72-4P 603985-73-5P 603985-74-6E
603985-75-7P 603985-76-8P 603985-77-9P
603985-78-0P 603986-04-5P, ER 804387
603987-34-4P 603987-35-5P 603987-75-3P
603987-93-5P, ER 806821 603988-36-9P

RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)

BN 603044-46-8 CAPLUS

1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8R,9R,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603045-42-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603045-44-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603045-45-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-[(methylsulfonyl)oxy]propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603045-46-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603151-24-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4S,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-37-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-64-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-65-5 CAPLUS
CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-70-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-72-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-73-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-74-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-75-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




$\equiv O$

RN 603985-76-8 CAPLUS

CN Methanesulfonamide, N-[2-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


 $\equiv O$

RN 603985-78-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603986-04-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-

tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-75-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-
8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-93-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-
8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8S,9S,11E)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-, (3S,4R,5Z,8S,9R,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603039-45-8P 603959-45-1P 603985-71-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-,
(3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Refine Search

Search Results -

Terms	Documents
MACROCYCLIC COMPOUND.TI. AND 540/\$	21

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

Recall Text  Clear Interrupt

Search History

DATE: Friday, July 06, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L7</u>	MACROCYCLIC COMPOUND.TI. AND 540/\$	21	<u>L7</u>
<i>DB=PGPB; PLUR=YES; OP=ADJ</i>			
<u>L6</u>	20040224936 or 20040004256 or 20060247448	3	<u>L6</u>
<u>L5</u>	2004224936 or 2004004256 or 2006247448	0	<u>L5</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L4</u>	L3 and (562/\$ or 560/\$ or 564/\$)	3	<u>L4</u>
<u>L3</u>	L2 and acrylic\$8 and palladium	7	<u>L3</u>
<u>L2</u>	polyhalo\$8 cinnamic acid	7	<u>L2</u>
<u>L1</u>	polhalo\$8 cinnamic acid	0	<u>L1</u>

END OF SEARCH HISTORY

Hit List

First Hit	Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS					

Search Results - Record(s) 1 through 10 of 21 returned.

1. Document ID: US 20070117154 A1

L7: Entry 1 of 21

File: PGPB

May 24, 2007

PGPUB-DOCUMENT-NUMBER: 20070117154

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20070117154 A1

TITLE: Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery

PUBLICATION-DATE: May 24, 2007

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Deslongchamps; Pierre	North Hatley		CA
Dory; Yves	Canton d'Eaton Cookshire		CA
Berthiaume; Gilles	Pte-Claire		CA
Ouellet; Luc	Sherbrooke		CA
Lan; Ruoxi	Fleurimont		CA

US-CL-CURRENT: 435/7.1; 514/183, 540/455

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

2. Document ID: US 20060205638 A1

L7: Entry 2 of 21

File: PGPB

Sep 14, 2006

PGPUB-DOCUMENT-NUMBER: 20060205638

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060205638 A1

TITLE: PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS

PUBLICATION-DATE: September 14, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Busacca; Carl Alan	Poughkeepsie	NY	US
Gallou; Fabrice	Paris	CT	FR
Haddad; Nizar	Danbury	VA	US

Hossain; Azad	Glen Allen	CT	US
Kapadia; Suresh R.	Danbury	VA	US
Liu; Jianxiu	Richmond	CT	US
Senanayake; Chris	Brookfield	CT	US
Wei; Xudong	Ridgefield	CT	US
Yee; Nathan K.	Danbury		US

US-CL-CURRENT: 514/9; 530/317, 540/460

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

3. Document ID: US 20060062728 A1

L7: Entry 3 of 21

File: PGPB

Mar 23, 2006

PGPUB-DOCUMENT-NUMBER: 20060062728

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060062728 A1

TITLE: Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using

PUBLICATION-DATE: March 23, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Brogan; John Bucknam	Niskayuna	NY	US

US-CL-CURRENT: 424/1.49; 534/11, 540/465, 540/473

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

4. Document ID: US 20050267018 A1

L7: Entry 4 of 21

File: PGPB

Dec 1, 2005

PGPUB-DOCUMENT-NUMBER: 20050267018

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050267018 A1

TITLE: Macrocyclic compounds as inhibitors of viral replication

PUBLICATION-DATE: December 1, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Blatt, Lawrence M.	San Francisco	CA	US
Andrews, Steven W.	Longmont	CO	US
Condroski, Kevin R.	Broomfield	CO	US
Doherty, George A.	Superior	CO	US

Jiang, Yutong	Longmont	CO	US
Josey, John A.	Longmont	CO	US
Kennedy, April L.	Denver	CO	US
Madduru, Machender R.	Boulder	CO	US
Stengel, Peter J.	Longmont	CO	US
Wenglowsky, Steven M.	Boulder	CO	US
Woodard, Benjamin T.	Golden	CO	US
Woodard, Laura	Golden	CO	US

US-CL-CURRENT: 514/9; 514/310, 530/317, 540/460

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

5. Document ID: US 20050209135 A1

L7: Entry 5 of 21

File: PGPB

Sep 22, 2005

PGPUB-DOCUMENT-NUMBER: 20050209135

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050209135 A1

TITLE: Process for preparing macrocyclic compounds

PUBLICATION-DATE: September 22, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Busacca, Carl Alan	Poughkeepsie	NY	US
Farina, Vittorio	Ridgefield	CT	US
Gallou, Fabrice	Danbury	CT	US
Haddad, Nizar	Danbury	CT	US
Wang, Xiao-Jun	Danbury	CT	US
Wei, Xudong	Ridgefield	CT	US
Xu, Jinghua	Bethel	CT	US
Xu, Yibo	New Milford	CT	US
Yee, Nathan K.	Danbury	CT	US
Zhang, Li	New Milford	CT	US

US-CL-CURRENT: 514/10; 514/314, 530/317, 540/465

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

6. Document ID: US 20050049234 A1

L7: Entry 6 of 21

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050049234

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050049234 A1

TITLE: Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

PUBLICATION-DATE: March 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Deslongchamps, Pierre	Sherbrooke	MA	CA
Dory, Yves	Cookshire		CA
Berthiaume, Gilles	Pointe-Claire		CA
Ouellet, Luc	Sherbrooke		CA
Lan, Ruoxi	Arlington		US

US-CL-CURRENT: 514/183; 540/460

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

□ 7. Document ID: US 20040115724 A1

L7: Entry 7 of 21

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115724

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115724 A1

TITLE: Macrocyclic compounds and their use

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Lowik, Dennis	Cambridge		GB
Lowe, Christopher Robin	Cambridge		GB

US-CL-CURRENT: 435/7.1; 540/472

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

□ 8. Document ID: US 7148347 B2

L7: Entry 8 of 21

File: USPT

Dec 12, 2006

US-PAT-NO: 7148347

DOCUMENT-IDENTIFIER: US 7148347 B2

TITLE: Process for preparing macrocyclic compounds

PRIOR-PUBLICATION:

DOC-ID DATE

US 20050049187 A1 March 3, 2005

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Abstract](#) | [Claims](#) | [KMC](#) | [Drawn D.](#)

9. Document ID: US 6281352 B1

L7: Entry 9 of 21

File: USPT

Aug 28, 2001

US-PAT-NO: 6281352

DOCUMENT-IDENTIFIER: US 6281352 B1

TITLE: Macrocyclic compounds as metalloprotease inhibitors

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Abstract](#) | [Claims](#) | [KMC](#) | [Drawn D.](#)

10. Document ID: US 6207826 B1

L7: Entry 10 of 21

File: USPT

Mar 27, 2001

US-PAT-NO: 6207826

DOCUMENT-IDENTIFIER: US 6207826 B1

** See image for Certificate of Correction **

TITLE: Macrocyclic compounds having nitrogen-containing linkages

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Abstract](#) | [Claims](#) | [KMC](#) | [Drawn D.](#)

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

Terms	Documents
MACROCYCLIC COMPOUND.TI. AND 540/\$	21

Display Format: - [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 11 through 20 of 21 returned.

11. Document ID: US 6107482 A

L7: Entry 11 of 21

File: USPT

Aug 22, 2000

US-PAT-NO: 6107482

DOCUMENT-IDENTIFIER: US 6107482 A

**** See image for Certificate of Correction ****

TITLE: Nitrogenous macrocyclic compounds

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Image View](#) | [Edit](#) | [Delete](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

12. Document ID: US 6054580 A

L7: Entry 12 of 21

File: USPT

Apr 25, 2000

US-PAT-NO: 6054580

DOCUMENT-IDENTIFIER: US 6054580 A

TITLE: Long-lived homogenous amide containing macrocyclic compounds

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Image View](#) | [Edit](#) | [Delete](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

13. Document ID: US 5871709 A

L7: Entry 13 of 21

File: USPT

Feb 16, 1999

US-PAT-NO: 5871709

DOCUMENT-IDENTIFIER: US 5871709 A

TITLE: Macrocyclic compounds as complexing compounds or agents, complexes of metal ions therewith and use thereof as contrast media for diagnostics and therapeutics

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Image View](#) | [Edit](#) | [Delete](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

14. Document ID: US 5583131 A

L7: Entry 14 of 21

File: USPT

Dec 10, 1996

US-PAT-NO: 5583131

DOCUMENT-IDENTIFIER: US 5583131 A

TITLE: Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Chemical Drawing	Claims	KMC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------------	--------	-----	----------

15. Document ID: US 5580900 A

L7: Entry 15 of 21

File: USPT

Dec 3, 1996

US-PAT-NO: 5580900

DOCUMENT-IDENTIFIER: US 5580900 A

TITLE: Macrocyclic compounds

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Chemical Drawing	Claims	KMC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------------	--------	-----	----------

16. Document ID: US 5523402 A

L7: Entry 16 of 21

File: USPT

Jun 4, 1996

US-PAT-NO: 5523402

DOCUMENT-IDENTIFIER: US 5523402 A

TITLE: Tripyridyl macrocyclic compounds

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Chemical Drawing	Claims	KMC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------------	--------	-----	----------

17. Document ID: US 5376663 A

L7: Entry 17 of 21

File: USPT

Dec 27, 1994

US-PAT-NO: 5376663

DOCUMENT-IDENTIFIER: US 5376663 A

TITLE: Macrocyclic compounds

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Chemical Drawing	Claims	KMC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------------	--------	-----	----------

18. Document ID: US 5326861 A

L7: Entry 18 of 21

File: USPT

Jul 5, 1994

US-PAT-NO: 5326861

DOCUMENT-IDENTIFIER: US 5326861 A

TITLE: Preparation of organic macrocyclic compounds

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Chemical Drawing	Claims	KMC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------------	--------	-----	----------

19. Document ID: US 5296489 A

L7: Entry 19 of 21

File: USPT

Mar 22, 1994

US-PAT-NO: 5296489

DOCUMENT-IDENTIFIER: US 5296489 A

** See image for Certificate of Correction **

TITLE: Immunosuppressive macrocyclic compounds

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Image](#) [Text](#) [Claims](#) [KMC](#) [Drawn D](#)

20. Document ID: US 5179087 A

L7: Entry 20 of 21

File: USPT

Jan 12, 1993

US-PAT-NO: 5179087

DOCUMENT-IDENTIFIER: US 5179087 A

TITLE: Macrocyclic compounds

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Image](#) [Text](#) [Claims](#) [KMC](#) [Drawn D](#)

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
MACROCYCLIC COMPOUND.TI. AND 540/\$	21

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 21 through 21 of 21 returned.

21. Document ID: US 4960882 A

L7: Entry 21 of 21

File: USPT

Oct 2, 1990

US-PAT-NO: 4960882

DOCUMENT-IDENTIFIER: US 4960882 A

TITLE: Proton ionizable macrocyclic compounds

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Specification](#) [Description](#) [Claims](#) [KMD](#) [Drawn D](#)

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
MACROCYCLIC COMPOUND.TI. AND 540/\$	21

Display Format: [-] [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)